DE602004015498D1 - Substituierte pyrazole als ppar-agonisten - Google Patents
Substituierte pyrazole als ppar-agonistenInfo
- Publication number
- DE602004015498D1 DE602004015498D1 DE602004015498T DE602004015498T DE602004015498D1 DE 602004015498 D1 DE602004015498 D1 DE 602004015498D1 DE 602004015498 T DE602004015498 T DE 602004015498T DE 602004015498 T DE602004015498 T DE 602004015498T DE 602004015498 D1 DE602004015498 D1 DE 602004015498D1
- Authority
- DE
- Germany
- Prior art keywords
- substituted pyrazole
- ppar agonists
- ppar
- agonists
- pyrazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 title 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0326747A GB0326747D0 (en) | 2003-11-17 | 2003-11-17 | Chemical compounds |
| GB0329462A GB0329462D0 (en) | 2003-12-19 | 2003-12-19 | Chemical compounds |
| PCT/EP2004/012965 WO2005049578A1 (en) | 2003-11-17 | 2004-11-15 | Substituted pyrazoles as ppar agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004015498D1 true DE602004015498D1 (de) | 2008-09-11 |
Family
ID=34621661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004015498T Expired - Fee Related DE602004015498D1 (de) | 2003-11-17 | 2004-11-15 | Substituierte pyrazole als ppar-agonisten |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080021030A1 (enExample) |
| EP (1) | EP1685113B1 (enExample) |
| JP (1) | JP2007511485A (enExample) |
| AR (1) | AR046625A1 (enExample) |
| AT (1) | ATE402926T1 (enExample) |
| DE (1) | DE602004015498D1 (enExample) |
| ES (1) | ES2311179T3 (enExample) |
| TW (1) | TW200526588A (enExample) |
| WO (1) | WO2005049578A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2006004027A1 (ja) * | 2004-07-01 | 2008-04-24 | 第一製薬株式会社 | ピラゾール誘導体 |
| AU2006217682A1 (en) * | 2005-02-28 | 2006-08-31 | Nippon Chemiphar Co., Ltd. | Activator for peroxisome proliferator activating receptor delta |
| NZ564916A (en) * | 2005-06-27 | 2011-03-31 | Exelixis Inc | Imidazole based LXR modulators |
| AU2007239283B2 (en) | 2006-04-18 | 2013-02-07 | Nippon Chemiphar Co., Ltd. | Activating agent for peroxisome proliferator activated receptor delta |
| KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| JP2010523623A (ja) * | 2007-04-11 | 2010-07-15 | グラクソ グループ リミテッド | Ｐ２ｘ７調節因子としてのピラゾール誘導体 |
| TWI440633B (zh) | 2008-04-15 | 2014-06-11 | Nippon Chemiphar Co | Activator of Activated Receptors for Peroxisome Producers |
| JP5621148B2 (ja) * | 2008-11-21 | 2014-11-05 | ラクオリア創薬株式会社 | ５−ｈｔ２ｂ受容体拮抗活性を有する新規ピラゾール−３−カルボキサミド誘導体 |
| TW201109335A (en) | 2009-08-04 | 2011-03-16 | Takeda Pharmaceutical | Heterocyclic compounds |
| MX2012006723A (es) * | 2009-12-15 | 2012-06-28 | Bayer Cropscience Ag | Procedimiento para la preparacion de derivados de acido 1-alquil-/1-aril-5-pirazolcarboxilico. |
| TWI508968B (zh) | 2010-02-08 | 2015-11-21 | Biota Scient Management | 用於治療呼吸道融合性病毒感染的化合物 |
| RU2017144535A (ru) | 2010-03-30 | 2019-02-18 | Версеон Корпорейшн | Мультизамещенные ароматические соединения в качестве ингибиторов тромбина |
| CN101870676B (zh) * | 2010-06-24 | 2011-09-07 | 山东大学 | 1-(2-肟基-2-苯基乙基)-3-苯基-1h-吡唑-5-甲酸乙酯衍生物及其制备与应用 |
| PL2968297T3 (pl) | 2013-03-15 | 2019-04-30 | Verseon Corp | Wielopodstawione związki aromatyczne jako inhibitory protezy serynowej |
| BR112015023214A8 (pt) | 2013-03-15 | 2019-12-24 | Verseon Corp | composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| EP3194369A4 (en) | 2014-09-17 | 2018-02-28 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
| GB201421083D0 (en) * | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| CA2977993A1 (en) | 2015-02-27 | 2016-09-01 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
| SG11201809922YA (en) | 2016-05-31 | 2018-12-28 | Kalvista Pharmaceuticals Ltd | Pyrazole derivatives as plasma kallikrein inhibitors |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| US10961273B2 (en) | 2016-08-16 | 2021-03-30 | Stealth Biotherapeutics Corp. | N-carboxyanhydride-based-scale synthesis of elamipretide |
| WO2018224455A1 (en) | 2017-06-07 | 2018-12-13 | Basf Se | Substituted cyclopropyl derivatives |
| RS63069B1 (sr) | 2017-11-29 | 2022-04-29 | Kalvista Pharmaceuticals Ltd | Dozni oblici koji sadrže inhibitor kalikreina plazme |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| TWI805699B (zh) | 2018-03-01 | 2023-06-21 | 日商日本煙草產業股份有限公司 | 甲基內醯胺環化合物及其用途 |
| CN111902408B (zh) | 2018-04-04 | 2023-11-14 | 日本烟草产业株式会社 | 杂芳基取代的吡唑化合物及其药物用途 |
| JP2021528405A (ja) * | 2018-06-18 | 2021-10-21 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲγｔのモジュレータとしてのアミド置換チアゾール |
| CN114206852A (zh) | 2019-08-09 | 2022-03-18 | 卡尔维斯塔制药有限公司 | 血浆激肽释放酶抑制剂 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3621775A1 (de) * | 1986-03-13 | 1988-01-07 | Thomae Gmbh Dr K | Neue substituierte thiazole und oxazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| BR9813019A (pt) * | 1997-10-02 | 2000-09-05 | Sankyo Co | Derivados do ácido amidocarboxìlico, agentes para diminuir a glicose do sangue, redutor de lipìdio, para melhorar a resistência à insulina, anti-inflamatório, para imuno regulagem, para inibir a aldose reductase, para inibir a 5-lipoxigenase, para a geração de supressor de peróxido de lipìdio, para ativar a ppar, para minorar a osteoporose, e, composições para a terapia ou prevenção da diabete melito, da hiperlipemia, da obesidade, da tolerância à glicose prejudicada, da resistência à insulina que não a igt, do fìgado gorduroso, de complicações diabéticas, da arterioesclerose, da diabete melito gestacional, da sìndrome do ovário policìstico, da artroesteìte, da artrite reumática, de doenças alérgicas, da asma, do câncer, de doenças auto imunes, da pancreatite, e de cataratas |
| EP1457490A1 (en) * | 1999-11-10 | 2004-09-15 | Takeda Chemical Industries, Ltd. | 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| PE20011010A1 (es) * | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
| JP3372923B2 (ja) * | 2000-02-25 | 2003-02-04 | エヌイーシーマイクロシステム株式会社 | 半導体集積回路 |
| AU2003224632A1 (en) * | 2002-03-01 | 2003-09-16 | Smithkline Beecham Corporation | Hppars activators |
-
2004
- 2004-11-12 TW TW093134800A patent/TW200526588A/zh unknown
- 2004-11-15 US US10/595,868 patent/US20080021030A1/en not_active Abandoned
- 2004-11-15 WO PCT/EP2004/012965 patent/WO2005049578A1/en not_active Ceased
- 2004-11-15 AT AT04818779T patent/ATE402926T1/de not_active IP Right Cessation
- 2004-11-15 JP JP2006538823A patent/JP2007511485A/ja active Pending
- 2004-11-15 AR ARP040104209A patent/AR046625A1/es unknown
- 2004-11-15 DE DE602004015498T patent/DE602004015498D1/de not_active Expired - Fee Related
- 2004-11-15 ES ES04818779T patent/ES2311179T3/es not_active Expired - Lifetime
- 2004-11-15 EP EP04818779A patent/EP1685113B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2311179T3 (es) | 2009-02-01 |
| US20080021030A1 (en) | 2008-01-24 |
| AR046625A1 (es) | 2005-12-14 |
| WO2005049578A1 (en) | 2005-06-02 |
| TW200526588A (en) | 2005-08-16 |
| EP1685113B1 (en) | 2008-07-30 |
| JP2007511485A (ja) | 2007-05-10 |
| ATE402926T1 (de) | 2008-08-15 |
| EP1685113A1 (en) | 2006-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004015498D1 (de) | Substituierte pyrazole als ppar-agonisten | |
| ATE377419T1 (de) | Substituierte 4-alkoxyoxazol derivate als ppar agonisten | |
| DE60308850D1 (de) | Pyridinoylpiperidine als 5-ht1f agonisten | |
| DE602004015724D1 (de) | Diazepinoindolderivate als kinaseinhibitoren | |
| DE602004024420D1 (de) | Chinazolinderivate als antitumormittel | |
| DE60308670D1 (de) | Substituierte indole als alpha-1 agonisten | |
| IL175139A0 (en) | Phenyl derivatives as ppar agonists | |
| ATE504559T1 (de) | Arylanilinderivate als agonisten des beta2- adrenergen rezeptors | |
| ATE421506T1 (de) | Neue benzimidazolderivate | |
| DE602004019555D1 (de) | Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone | |
| ATE369358T1 (de) | Substituierte benzoylderivate als herbizide | |
| DE602005015204D1 (de) | Oxadiazolonderivate als ppar-delta-agonisten | |
| DE602004004295D1 (de) | 6-ä(substituiertes)phenylütriazolopyrimidine als antikrebsmittel | |
| NL1027545A1 (nl) | Chinolonen als antibacteriele middelen. | |
| ATE365161T1 (de) | Pyrazolverbindungen | |
| ATE394372T1 (de) | G-lactamderivate als prostaglandinagonisten | |
| ATE410428T1 (de) | Pyrroloä2,1-cüä1,4übenzodiazepine als vasopressin-agonisten | |
| DE502004005180D1 (de) | Stereomikroskop | |
| NL1024983A1 (nl) | Morfolinen als dopamineagonisten. | |
| ATE364601T1 (de) | Substituierte pyrazolverbindungen | |
| EP1687399A4 (en) | MODIFIED LUCIFERASE | |
| NL1025542A1 (nl) | Geanelleerde heteroarylcarbonzuren als PPAR-agonisten. | |
| FI20035067L (fi) | Parveke tai vastaava | |
| ATE459618T1 (de) | 3-piperidinylisochroman-5-ole als dopaminagonisten | |
| DK1633719T3 (da) | Substituerede spirobenzazepiner |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |